^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Navelbine oral (vinorelbine tartrate oral)

    i
    Other names: VRL
    Associations

    News

    Trials
    Company:
    Pierre Fabre
    Drug class:
    Tubulin polymerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    8d
    Evolutionary Therapy for Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=28 --> 12
    Enrollment closed • Enrollment change
    |
    FOXO1 (Forkhead box O1)
    |
    doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    1m
    A single-arm clinical study of subcutaneous injection of enolumab combined with oral vinorelbine as the first-line treatment for elderly patients with advanced non-small cell lung cancer (ChiCTR2500109581)
    P2, N=62, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • EGFR negative
    |
    Navelbine oral (vinorelbine tartrate oral)
    3ms
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov)
    P3, N=27, Active, not recruiting, Spanish Breast Cancer Research Group | Trial primary completion date: Jun 2025 --> Jun 2026 | Trial completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    4ms
    SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=200, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA (Breast cancer early onset)
    |
    gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)
    4ms
    A single-arm, single-center, phase II clinical study of ivorximab combined with metrometric chemotherapy in the treatment of advanced or metastatic squamous NSCLC after failure of second-line or more systemic therapy (ChiCTR2500106870)
    P2, N=30, Not yet recruiting, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University Affiliated Tumor Hospital
    New P2 trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Navelbine oral (vinorelbine tartrate oral)
    4ms
    VINOREAL: To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment (clinicaltrials.gov)
    P=N/A, N=368, Recruiting, Pierre Fabre Medicament | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2026 --> Feb 2028
    Enrollment open • Trial primary completion date
    |
    Navelbine oral (vinorelbine tartrate oral)
    5ms
    Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
    The most common grade 3-4 AEs that we observed were neutropenia (17.1%), leukopenia (9.8%) and diarrhea (9.8%). Continuous administration of anlotinib combined with oral vinorelbine demonstrates to be efficacious and well tolerated for refractory HER2 negative ABC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Focus V (anlotinib) • Navelbine oral (vinorelbine tartrate oral)
    6ms
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    7ms
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (clinicaltrials.gov)
    P2, N=135, Recruiting, St. Jude Children's Research Hospital | Phase classification: P1/2 --> P2 | N=100 --> 135
    Phase classification • Enrollment change
    |
    TP53 (Tumor protein P53) • FOXO1 (Forkhead box O1) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    8ms
    Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) (clinicaltrials.gov)
    P2, N=178, Active, not recruiting, Fudan University | Unknown status --> Active, not recruiting | Trial completion date: May 2021 --> Jun 2027 | Trial primary completion date: May 2021 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Navelbine oral (vinorelbine tartrate oral)
    9ms
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov)
    P3, N=27, Active, not recruiting, Spanish Breast Cancer Research Group | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    10ms
    Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis (clinicaltrials.gov)
    P2, N=102, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    capecitabine • cyclophosphamide • Navelbine oral (vinorelbine tartrate oral)